EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling

Joanna Parkinson iD, Corina Dota, Christian Källgren, Christer Gottfridsson, Magnus Bjursell, Shira Perl, Thomas Kӧrnicke, Dinko Rekić, Susanne Johansson iD

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15637 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Joanna Parkinson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Allopurinol, Long QT Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This thorough QT/QTc (TQT) study was conducted to evaluate the risk of QT prolongation for verinurad when combined with allopurinol. Verinurad is a novel, urate anion exchanger 1 inhibitor that reduces serum urate levels by promoting urinary excretion of uric acid. It is co‐administered with a xanthine oxidase inhibitor.

Methods

The TQT study (NCT04256629) was a randomized, placebo‐controlled, double‐blind, three‐period, crossover study, conducted in healthy volunteers. A total of 24 participants received single doses of verinurad 24 mg extended release, 40 mg immediate release formulation (both co‐administered with allopurinol 300 mg), and matching placebos. The primary endpoint was baseline‐ and placebo‐adjusted Fridericia‐corrected QTcF interval (ΔΔQTcF) at the concentration of interest. A prespecified linear mixed‐effects concentration–QTc model was used to estimate the primary endpoint. Time‐matched 12‐lead digital electrocardiograms and plasma concentrations were measured at baseline and up to 48 h after dose in each participant.

Results

Estimated ΔΔQTcF at the highest clinically relevant scenario (76 ng/mL) was −2.7 msec (90% confidence interval [CI]: −4.6, −0.8). Furthermore, the upper 90% ΔΔQTcF CI was estimated to be below 10 msec at all observed verinurad concentrations. Supratherapeutic verinurad dose was used to achieve exposures eightfold higher than the highest clinically relevant exposure, thus waiving the need for positive control.

Conclusions

As the effect on ΔΔQTcF was below the threshold for regulatory concern (10 msec) at the supratherapeutic exposure, it can be concluded that verinurad and allopurinol treatment does not induce QTcF prolongation at the highest clinically relevant exposures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AllopurinolLong QT SyndromeHumansMoxifloxacinCross-Over StudiesUric AcidHeart RateDose-Response Relationship, DrugElectrocardiographyDouble-Blind MethodNaphthalenesPropionatesPyridines

Stichwörter der Autor:innen

QTTQTURAT1verinurad

Substanzen

MoxifloxacinAllopurinolUric AcidverinuradNaphthalenesPropionatesPyridines

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Gothenburg, Sweden.
  • Cardiovascular Safety Center of Excellence and Safety Knowledge Group, Global Patient Safety, Oncology R&D, AstraZeneca, Gothenburg, Sweden.
  • Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Early Phase Clinical Unit, Parexel International, Berlin, Germany.

ORCID-Profile: Joanna Parkinson, Susanne Johansson

Förderung

  • AstraZeneca

Zitieren

APA

Parkinson, J., Dota, C., Källgren, C., Gottfridsson, C., Bjursell, M., Perl, S., Kӧrnicke, T., Rekić, D., & Johansson, S. (2023). Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15637

Vancouver

Parkinson J, Dota C, Källgren C, Gottfridsson C, Bjursell M, Perl S, et al. Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15637

BibTeX
@article{Parkinson2023,
  author = {Parkinson, Joanna and Dota, Corina and Källgren, Christian and Gottfridsson, Christer and Bjursell, Magnus and Perl, Shira and Kӧrnicke, Thomas and Rekić, Dinko and Johansson, Susanne},
  title = {Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15637}
}
Kostenlos starten →